Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary
February 17, 2021
Earnings Call Speaker Segments
Operator
operatorHello, everyone, and welcome to the conference call on Palatin Technologies' operating results for the second quarter of fiscal year 2021. Please note that this call is being recorded. Before we get into our remarks, I want to point out that anything Palatin states that isn't a historical fact could be a forward-looking statement. Such statements rest on assumptions that might or might not turn out to be accurate, and actual results could differ materially from what is anticipated because of various risks and uncertainties covered in the company's latest filings with the Securities and Exchange Commission. I'd ask you to weigh those risks and uncertainties carefully when evaluating these forward-looking statements and Palatin's prospects. At this point, I'll hand the call over to today's host, Dr. Carl Spana, Palatin Technologies' President and Chief Executive Officer. Sir, please go ahead.
Carl Spana
executiveThanks, and good morning, everyone, and welcome to the Palatin Technologies call for the second quarter of fiscal year 2021. This is Dr. Carl Spana, Palatin's CEO and President. Joining me today is Steve Wills, our Executive Vice President, Chief Financial Officer, and Chief Operating Officer. During this call, we'll share updates on both finances and operations. At this point I'll hand things over to Steve, who will cover the financial updates along with an update on Vyleesi. Steve?
Steve Wills
executiveThanks, Carl. Good morning, everyone. Turning to the financial highlights for the second quarter that ended December 31, 2020: we recorded a net loss of $10 million for the quarter, or $0.04 per share, versus a net loss of $5.2 million, or $0.02 per share, in the same quarter of 2019. Total operating expenses came in at $9.1 million for the quarter ended December 31, 2020, compared with $5.7 million in the comparable quarter of 2019. The higher net loss and operating expenses were mainly due to commercial expenses tied to Vyleesi and to the PL-9643 Phase 2 study for treating dry eye disease. Notably, we incurred a number of non-recurring expenses related to Vyleesi during the quarter ended 12/31/20. Looking ahead over the next few quarters, we expect operating expenses to decline before we begin our dry eye treatment trial as well as the colitis trials, which we aim to start around mid-year. At December 31, 2020, cash and cash equivalents stood at $72.2 million, with $4.7 million in accounts receivable, compared with $82.9 million in cash and cash equivalents and no accounts receivable at June 30, 2020. Palatin carries no outstanding debt. A few remarks now on our Vyleesi program. To help frame where we've been and where we stand with Vyleesi, I think it's useful to recap some of the history.
Steve Wills
executiveWhat we got back from AMAG last year was a program that required work. When the transfer happened, sales and marketing support ranged from minimal to nonexistent. We're aware of that. And that's partly why we got $12 million upfront, with another $4.3 million owed to us by AMAG/Covis on March 31, 2021. To make sure patients could still access Vyleesi and to keep regulatory compliance intact as it came back to Palatin, we signed a transition services agreement and, importantly, began rebuilding the sales and marketing commercial infrastructure along with restructuring and streamlining the operational distribution network, including processes and procedures aimed at improving the patient access experience, healthcare provider interaction, and boosting insurance reimbursement. On this call we'll give you more specifics about some of our Vyleesi efforts. Our disciplined plan and investment are producing positive trends and returns, with a significant increase in payer reimbursement and double-digit gains in month over month prescription numbers continuing through January of 2021. Carl?
Carl Spana
executiveThanks, Steve. We're still running our operations under the conditions created by the COVID-19 pandemic, which remains ongoing. To this point, we believe the adjustments we've made have let us keep moving our preclinical, clinical, and commercial programs forward while keeping our employees, our patients, healthcare providers, and partners safe. As we disclosed earlier, back in 2020, we re-acquired Vyleesi from AMAG Pharmaceuticals. And as a reminder, AMAG's divestiture of Vyleesi rested on a strategic and operational change at AMAG, not on what Vyleesi might be worth. Steve covered the details of our commercial plan for Vyleesi, and there are several accomplishments I'd like to highlight. Once we re-acquired Vyleesi, we carried out an extensive evaluation of the commercial infrastructure and the patient experience. It's a strain to say that the commercial infrastructure wasn't functioning properly, and it was really producing a very sub-optimal patient experience and very unfavorable economics. Under Steve's directions, we have rebuilt the Vyleesi commercial infrastructure. And as he mentioned, this is a ground up rebuild from distribution, telemarketing, specialty pharmacies — all this had to be redone — and we've expanded the patient access of the product. And we believe that the changes we have put in place over the past six months will dramatically improve the patient experience, patient access, relationships with prescribers and the profitability of Vyleesi.
Carl Spana
executiveAt this point, we're able to concentrate our work on boosting Vyleesi prescription figures and on talks with potential partners. A bit ahead of schedule, early data from the geo-targeting push we have underway is starting to lift Vyleesi prescriptions and reimbursement, and we're working to grow that further. These wins will leave us well placed to show Vyleesi's potential value in a cost-effective way and to reach our end goal of re-licensing Vyleesi to a dedicated partner — securing continued availability of Vyleesi as a treatment option for premenopausal women with hypoactive sexual desire disorder, along with a substantial return on our investment. Turning to our clinical and preclinical pipeline, those programs keep moving forward, and the past quarter brought some pretty exciting results. As a reminder, our main scientific focus is the melanocortin system, which plays a part in regulating energy balance, including food intake, sexual function and resolution of inflammatory responses. Our first melanocortin program rested on the role that the melanocortin system plays in regulating sexual function. That research led to the discovery of Vyleesi and to its FDA approval as the first on-demand treatment for premenopausal women with hypoactive sexual desire disorder. Worth noting as well, Vyleesi was also the first melanocortin-based therapeutic to win FDA approval.
Carl Spana
executiveRight now, our research efforts center on creating medicines that act on the melanocortin system's capacity to calm or shut down inflammation and lessen fibrosis. We're aiming to assemble a portfolio of melanocortin-based therapeutics that we think hold considerable promise for addressing a range of ocular diseases. We've produced drug candidates at the clinical stage for ocular conditions including dry eye disease, other corneal disease indication, non-infectious uveitis, and retinal diseases. In addition, we have an orally administered drug candidate at the clinical stage for gastrointestinal disease such as ulcerative colitis. The first of our melanocortin therapeutics is topically delivered PL9643. Back in December of 2020, we announced positive results from our Phase 2 dry eye disease study. That study achieved its primary objective, namely supplying the data needed to keep advancing PL9643. Dry eye disease, also called keratoconjunctivitis sicca, impacts the cornea and conjunctiva of the eye, producing irritation, redness, pain, and blurry vision. Its causes differ widely, and we believe that by activating the melanocortin system, locally delivered PL9643 will lessen or resolve the inflammation behind many of the negative aspects of dry eye disease. The PL9643 Phase 2 study was a multi-center, randomized control study that compared topically delivered PL9643 against placebo across a 12-week treatment period.
Carl Spana
executiveThe trial included 160 participants and assessed safety, tolerability, and efficacy as measured by improvement across multiple signs and symptoms of dry eye disease. The co-primary endpoints were inferior fluorescein corneal staining, a sign of dry eye disease, and ocular discomfort, a symptom of dry eye disease. The study also featured a number of secondary endpoints to give a detailed picture of how topically delivered PL9643 affects improvement in the signs and symptoms of dry eye disease. And looking at the data overall, statistically significant improvements across multiple signs and symptoms were seen in a moderate to severe patient population following two weeks of dosing and at the 12-week visit. No safety signals were identified, and PL9643 showed excellent ocular tolerability. That said, statistical significance for the primary endpoints was not reached in the overall enrolled population, which included mild, moderate, and severe patients. Among the sub-populations of moderate to severe patients, PL9643 reached statistical significance at week two and week 12 for multiple signs, including inferior, superior, and total corneal fluorescein staining, temporal, nasal, and total conjunctival staining, <<inaudible>> peptide, and multiple ocular symptoms including ocular discomfort. In addition, multiple sign and symptom measures trended toward significance.
Carl Spana
executiveI believe it's worth pointing out that this was the first dry eye disease trial we ran with PL9643, and the active results were broad-based, demonstrating improvement in inflammation of both the cornea and the conjunctiva. Positive effects appeared as early as two weeks and were sustained throughout the treatment period. The study results have enabled us to pin down the patient population endpoint, the time point and the regulatory pathway for continuing development of PL9643 as a dry eye disease treatment. Right now we're getting ready for an end of Phase 2 meeting with the FDA, and for launching the Phase 2/3 PL9643 clinical study in dry eye disease, which is targeted to begin in mid-2021 with data readouts in the first half of 2022. As a reminder, detailed data from the reasonably concluded Phase 2 study will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology in early May of this year. In summary, the emerging profile of PL9643, with its rapid therapeutic onset and excellent ocular tolerability profile, is a potentially distinct advance in dry eye therapy. If the results are confirmed in market clinical studies, we believe that PL9643 has a potential for substantial penetration into the multi-billion dollar dry disease market.
Carl Spana
executiveLike we said earlier on this call, we think therapeutics built on melanocortin have the potential to address a range of ocular diseases. You can split ocular disease treatments into two broad groups: front of the eye, or the anterior segment, and back of the eye, or the posterior segment. Dry eye disease and corneal transplant are examples within the anterior segment. We're assessing clinical candidates for further anterior segment indications, and we expect to make a decision on our next anterior segment disease indications by mid-2021. Various retinopathies and uveitis fall under posterior segment diseases. By mid-2021 as well, we plan to move a clinical candidate forward for a retinal disease indication. Turning to our oral formulation of PL8177 for ulcerative colitis, we're carrying out the activities needed to run a Phase 2 proof-of-concept study, which is targeted to begin patient enrollment in the second half of 2021, with data readout in 2022. This will be our first clinical study designed to assess the potential of a selective melanocortin 1-receptor agonist as a treatment for ulcerative colitis. The study will assess the safety and potential efficacy of orally delivered PL8177. Should results be positive, they will support our efforts to license PL8177.
Carl Spana
executiveOn the pulmonary side, and specifically for PL8177 as a possible therapy for COVID-19 patients, we're still carrying out the work needed to open an IND and run clinical trials. In COVID-19 infection, PL8177 could potentially lessen the inflammation and lung fibrosis that come with the illness. As we've noted on earlier calls, in our press releases and in our 10-K, the environment for running clinical trials in COVID-19 patients shifts quickly, and that has affected trial design, risk and our capacity to launch new studies in this patient group. Given the risks and uncertainties around doing clinical research in COVID patients, the PL8177 COVID-19 study that has been initiated hinges on outside funding. We're still pursuing external support and hope to secure backing for this highly promising program. Lastly, building on our research into a naturally occurring peptide system, our candidate PL3994 — a selective natural peptide receptor A agonist — is now being assessed in a Phase 2 trial involving heart disease patients with preserved ejection fraction. That trial is being run with two major academic medical centers and is funded through a grant from the American Heart Association. Enrollment started late last year, and the study is ongoing at present.
Carl Spana
executiveWe expect preliminary data during 2022. More details about our programs are available on our website, www.palatin.com. When the pandemic hit, executive management, employees and the board of directors moved quickly to adjust how we run our business operations, and we've been able to keep advancing our programs. In addressing the COVID-19 pandemic, we took immediate steps to ensure the safety of our employees, patients, and healthcare partners. Our ability to advance, our development programs, and our strong cash position will allow us — Palatin — to emerge from the pandemic in a strong position. Our Vyleesi commercial activities have made significant progress. Under Steve Wills' direction, we have put in place an additional commercial team that has addressed the deficiencies we inherited from AMAG Pharmaceuticals. We have now begun selective marketing of Vyleesi. We continue working with our Chinese and Korean partners, which are now advancing Vyleesi into clinical studies and supporting their regulatory submissions. For a dry eye disease program, we completed our first Phase 2 study as part of the results and are preparing for the start of the Phase 2/3 study in mid-2021. In addition, we continue building our melanocortin based ocular therapeutics product portfolio with additional clinical studies and new indications starting in the second half of 2021.
Carl Spana
executiveLooking ahead to the remainder of 2021, our pipeline of novel clinical candidates is strong, and our attention will stay fixed on moving those candidates forward. To close, I want to express appreciation to the Palatin team and to each of our partners for adapting so quickly to a new working environment and for their ongoing commitment to advancing our programs. We will now take questions on the call.
Operator
operatorAnd our initial question comes from John Newman at Canaccord. Go ahead, please.
Carl Spana
executiveHello there, John.
John Newman
analystHey, guys. Thanks for taking my question. Actually, I had two questions. The first is for Steve. Steve, I'm just curious what additional steps you'd like to take with the commercial approach for Vyleesi. Obviously, you've done a lot to this point already, but I'm just curious what the next steps are over the next few quarters? And then, also curious regarding the partnership discussions for Vyleesi; I wondered if you believe those are really tied in any way to the commercial progress for Vyleesi or if that is really independent and sort of more focused on longer term potential there? Thanks.
Steve Wills
executiveOkay, thank you John. It’s Steve here. So when it comes to Vyleesi and how we’re taking it to market commercially, like I said earlier and Carl shed some additional light on, there were certain infrastructure-related issues that simply needed fixing. To be a little more precise, the prior authorization process wasn’t being carried out the way it ought to be. That prior authorization process—handled by the specialty pharmacies—is the mechanism through which we receive reimbursement for the product. So the level of reimbursement was considerably below where we believe it ought to be, particularly given how much coverage we have established for covered lives with the payors. That was a definite top-priority item we’ve gone after, and we think it has clearly gotten better. I expect that by the end of February it will be where we believe it should be. Beyond that, we’ve gone after the—telemedicine represents a fairly important channel. So we’ve overhauled that experience for the patient and made it more streamlined. And our work with the pharmacies has also been ongoing, and that as well, we believe, will be where we think it should be by the end of February.
Steve Wills
executiveFor Vyleesi’s value, those metrics tied to tenants matter a great deal. More insurance coverage translates into higher profitability, which shapes the patient experience. On top of that, the ATP interaction in this area is clearly a plus. And that is going to fuel script growth. As for the other portion of your question—the brand—the steps we are taking at present will raise the brand’s value. Should that value rise, we will find ourselves in a far stronger position when it comes to our dialogue with possible partners and collaborators about relicensing Vyleesi for the U.S. as well as other regions. During the previous call, I noted that we had slowed certain of those talks involving other regions, since our aim was to focus on rebuilding the Vyleesi brand within the U.S. Discussions are still underway. We expect to have partnerships across the rest of the world later in the year. And in the U.S., that is our strategy. We are in dialogue, we believe it will be a later-in-the-year event, and frankly that reflects certain matters that we judged it sensible to adjust in the Vyleesi commercial operations. So, was that a reasonably responsive answer, John?
John Newman
analystYes, thanks so much.
Operator
operatorMichael Higgins from Ladenburg Thalmann has our next question. Please go ahead.
Michael Higgins
analystThanks. Thanks everyone for taking the questions, and congratulations on the continued execution. I have a couple on Vyleesi, if I could begin here. Could you give us a bit of assistance regarding the reimbursements? You said that it has been rising. Can you provide us some level of detail on how many lives are covered and how that has been shifting recently?
Steve Wills
executiveYeah, this is Steve — Michael, I'll take that one. When we were first getting going — and let me also walk through how these lives get counted, because if you actually add them all up, the total would exceed 100%. Even so, we've grown the covered lives and, more importantly, we've grown the contracts and how covered lives get applied within those contracts. So, we have contracts in place. A number of them were already in place with AMAG. Some have been transferred over, and some were added just for Palatin — every contract right now sits in Palatin's name. And we've been working with our Market Access group to refine those contracts, really tailoring them to Vyleesi and to where we should be positioned. That, along with putting in place a more robust prior authorization process, has produced multiple insurance coverage wins from a — we might've been at XX when we first started and now we're at multiples of that X. From a covered life standpoint, using the way most people do the calculations, we're in that 70% range, and even though we've only recently reached that 70% range, that's considered very good coverage. You're not going to get 100% coverage. The majority is the big boys.
Steve Wills
executiveAnd in this landscape, there are only a limited number of major players, and those are the ones we already have in place. The one or two we don't yet have are among the regional players. Our market access group is pushing that conversation forward. And we expect — and I would certainly hope we expect — that those extra contracts and agreements will be secured over the coming several months.
Michael Higgins
analystRight, that’s genuinely useful — thanks for going into that much detail. On the question of how profitable this asset is quarter by quarter, clearly, as you’ve hinted at and laid out so thoroughly, there’s been a great deal of marketing and a lot of rebuilding from the ground up that you’ve completed. Costs look to be roughly $1.1 million across the past 2 quarters — is that a reasonable figure to use going forward, along the lines of that increase?
Steve Wills
executiveIt's going to vary somewhat, depending on what activities we have underway. During the fourth quarter, we launched a geo-targeting digital marketing campaign. We're currently in the middle of overhauling it, now that the data has come back and we can see where adjustments are needed — whether that means a particular region or pursuing a different avenue landscape for the digital marketing. There — we did incur several one-time expenses, call them non-recurring, in the fourth quarter, but that figure, I mean, it could move — I don't believe it will drop much, maybe if you want a thousand, though it could equally rise by a few hundred thousand, just depending on what's transpiring in that mark.
Michael Higgins
analystAll right, that's excellent, thank you. This is the final question, on Vyleesi, regarding the timeline for a partnership. My assumption is that you're putting in some work to get that product going. Can you hint at any kind of threshold at which you'll step up your partnering activity? I don't imagine you'd want to partner before you can truly show that consumers genuinely want this product. And once you have that momentum, that's likely the ideal moment to bring in a partner. Might you say that happens this year, or is it more of a 2022 outlook? Thanks.
Steve Wills
executiveLook, I really do believe that dialogue is going to pick up in 2021 as we broaden the scope. With a brand like this, the two chief things partners are after are the script growth — clearly the refill growth too — plus the insurance coverage. So we think we're hitting all three of those areas, and we're demonstrating meaningful progress. And we won't sit around until year-end before kicking off those conversations. A number of them are already underway, but I do — Carl and I both expect those talks will definitely ramp up in the back half of the year. And should things line up, we're not against moving sooner rather than later. It genuinely comes down to what kind of deal it is, who the partner is, how the collaboration works, but that's the strategy we're running. So we license the product and put in a — what we describe as a reasonable and measured amount. I mean, we've got an approved product here. This is a product that has brought us $165 million since the first quarter of 2017. It's a highly valuable asset. So we want to devote a certain level of attention that Palatin is able to, but it won't be the same degree of attention a far bigger partner — one that's, say, committed in the female healthcare spaces — would give it.
Steve Wills
executiveAs you can see from our presentation, there are several other programs we have that were moving in the direction of — around autoimmune and anti-inflammatory — but here we believe we have a strong asset, and we intend to build up its value. And at a later point — whether that comes later this year or during the first half of 2022 — we will be out-licensing our product.
Michael Higgins
analystThanks for all that detail. I’ve just got one final question, and it’s about PL9643. Could you remind us once more what numbers are required for the NDA filing and how large the upcoming trial is? What I’m getting at, I suppose, is whether you believe that will be all you need or whether you’ll need the Phase 3. It’s somewhat of an old question, but if you could give us an update, thanks.
Steve Wills
executiveYes. I believe the connection cut out a bit on your end, so let me attempt to walk through the pathway over the line. So, at this point, we have finished our first study. The results have us quite encouraged, and we will — as I mentioned, we will lay it all out in the presentations taking place somewhat later in the year. So the next trial, which calls for a Phase 2/3, is going to examine both — once again it will have co-primary end points. There will be a sign and a symptom. The final size has not been settled as of yet, but statistically speaking, that isn't necessary. We could perhaps manage with 60 to 80 per arm and observe — and have solid power. So we will likely go above that simply because we — for safety reasons, since we generally want extra safety data to back this up as a regulatory submission. And what the FDA requires would be two trials. Two trials will be run in which you achieve both a sign and a symptom across both trials. So what we would aim to do at this point is to launch this trial in mid-year. We will be making use of an adaptive clinical trial design.
Steve Wills
executiveSo around Q3 of this year — and likely Q4 as well — we should start to get a read on how that trial is progressing. At that point, we'll decide how fast we want to launch the second Phase 3 trial, and that launch could come as early as late this year, or probably by Q1 of next year at the latest.
Michael Higgins
analystAll right.
Steve Wills
executiveAnd as I mentioned, these studies will likely enroll roughly 200 to 300 patients apiece, and that's probably about where they'll land.
Michael Higgins
analystAll right, that’s very useful. I appreciate it. Thank you, Carl. Thank you, Steve.
Carl Spana
executiveThanks, Michael.
Operator
operatorThat brings today’s Q&A portion to a close. At this point, I’d like to hand the conference <<inaudible>>.
Carl Spana
executiveWell, I'm not sure whether we're still connected. But assuming we are, we truly appreciate your joining Palatin Technologies' conference call for the second quarter of fiscal year 2021. Stay safe, and we look forward to bringing you further updates during the next quarter. Thank you, and have a wonderful day.
Operator
operatorThat brings today's call to a close. Thanks for joining us. You're free to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.